Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques
December 10 2019 - 8:30AM
Business Wire
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
joint preservation and regenerative therapies company with products
leveraging its proprietary hyaluronic acid (HA) technology
platform, today announced it will commence the full U.S. commercial
launch of TACTOSET, its surgically delivered therapy for bone
repair procedures, at the Orthopaedic Summit 2019: Evolving
Techniques (OSET), which will take place December 11-14, 2019 at
the Bellagio Hotel in Las Vegas, NV.
“We are proud to commence the full-scale launch of TACTOSET, our
first surgically delivered regenerative therapy in the U.S. sold
through our hybrid commercial sales channel,” said Joseph Darling,
President and Chief Executive Officer of Anika Therapeutics.
“TACTOSET has already surpassed our initial goals of onboarding
five distributor agents and being present in ten surgical centers
in 2019. OSET is the perfect venue to take the next step with the
therapy and mark this important milestone in Anika’s transformation
to a global commercial company as a premier gathering of Sports
Medicine and Arthroscopic Surgery Orthopedists from across the
globe.”
TACTOSET has been developed for the treatment of bone voids and
other bone defects of the skeletal system caused by trauma or
age-related degeneration. TACTOSET is Anika’s first product to
launch under its U.S.-based hybrid commercial model. This therapy
combines calcium phosphate, an established precursor to the mineral
component of bone, with Anika’s proprietary hyaluronic acid, which
enhances flow and tactile feel during administration to improve
ease of use and procedural efficiency.
“I continue to be pleased with TACTOSET’s unique ease-of-use in
my surgical practice, which has led to a reduction in operating
room time for the procedure,” said Dr. John Tierney, an Orthopaedic
Surgeon at New England Baptist Hospital, President of the Greater
Boston Orthopaedic Center. “I am already a repeat user, and I
believe that many of the orthopaedic surgeons in attendance at OSET
2019 will recognize the differentiated benefits that this product
can provide to their practices.”
Anika will showcase its TACTOSET bone repair therapy at OSET
booths 112 and 114. The Orthopaedic Summit, attended by over 900 of
the world’s leading orthopaedic professionals, will feature
cutting-edge lectures, rapid-fire debates, lunch and dinner
symposia, cadaver lab sessions, and an international perspective on
the latest techniques in arthroplasty, arthroscopy, and
rehabilitation of the knee, shoulder, foot and ankle, hip, spine,
hand, wrist and elbow.
About OSET
The OSET (Orthopaedic Summit: Evolving Techniques) is the
premier gathering of more than 900 internationally renowned
orthopaedic surgeons, in sports medicine, trauma, spine, total
joint (knee, shoulder, hip), foot & ankle, arthroplasty, and
arthroscopy, plus fellows, residents, physician assistants, nurse
practitioners, physical therapists, and athletic trainers from
across the globe. The 3.5 day, 35 CME-accredited Orthopaedic Summit
2019, will include cutting-edge, industry-sponsored, cadaveric and
live surgical demonstrations (non-CME), lunch time symposia,
rapid-fire debates, small group discussions all with an
international perspective on the latest techniques in arthroplasty
and arthroscopy, as well as sports medicine of the knee, shoulder,
hip, elbow/wrist, foot/ankle, trauma and spine. It will feature the
5th Annual Fellow & Resident Summit and the Advanced
Practitioner Summit to enhance collaborations and provide
networking opportunities to enhance patient care.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global,
integrated joint preservation and regenerative therapies company
based in Bedford, Massachusetts. Anika is committed to delivering
therapies to improve the lives of patients across a continuum of
care from osteoarthritis pain management to joint preservation and
restoration. The company has more than two decades of global
expertise commercializing more than 20 products based on its
proprietary hyaluronic acid (HA) technology platform. For
more information about Anika, please visit
www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191210005044/en/
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial Officer
investorrelations@anikatherapeutics.com
For Media Inquiries: W2O Group Jeremy Berrington, 312-241-1995
jberrington@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Sep 2023 to Sep 2024